PPARD and metabolic syndrome: Given that PPARβ/δ is a promising molecular target in the prevention and treatment of metabolic diseases such as dyslipidemia, obesity and diabetes, we suggest a careful evaluation of the use of high-affinity PPARβ/δ agonists such as GW501516, which is currently in phase IV clinical trials for the treatment of dyslipidemia (Ooi et al, 2011).